Work

Supplementary Figure 1 from A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 1. Pharmacokinetics of CPI-613 infused over 1 hour. Plasma CPI-613 levels following a 1 or 2 hour infusion shown on day 1 and day 6 on a linear scale. The number of patients in each analysis is indicated by n. **=p<0.05.

DOI: 10.1158/1078-0432.22457619

Authors: Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361970968

Cites:

Cited by:

Related to: 10